Department of Chemistry, Syracuse University, Syracuse, New York 13244, USA.
Langmuir. 2010 Jun 1;26(11):8914-24. doi: 10.1021/la904695a.
We report on adsorption and release of the anticancer drugs cisplatin and transplatin from mesoporous silica nanomaterials, emphasizing the differences between cisplatin and its much less toxic isomer. Two types of particles, MCM-41 and SBA-15, were used, either as just synthesized or after calcination to remove the templates. The particles were characterized by TEM, nitrogen physisorption, and elemental analysis. The UV-vis spectra of cisplatin and transplatin were obtained and the intensities of several bands (205-210 nm, 210-220 nm, 220-235 nm, and 300-330 nm) were found proportional to drug concentrations, allowing their use for measuring drug concentration. To evaluate drug adsorption by nanoparticles, nanoparticles were incubated in drug solutions and removed by centrifugation, after which the supernatants were scanned by spectrometer to determine drug remaining. It was found that calcined MCM adsorbed less cisplatin or transplatin per particle than as-synthesized MCM. SBA nanoparticles adsorbed slightly more cisplatin than MCM, and slightly less transplatin. Measurements of drug adsorption as a function of time show that drug is rapidly adsorbed by all particles studied. This rapid adsorption is probably associated with adsorption of drug on the external surfaces of the particles as well as the possible physisorption within the surfactant assemblies or by replacing the surfactant molecules or ions in the case of the as-synthesized materials. For calcined SBA particles, it is followed by a slow take-up of drug, perhaps due to the internal pores. There is no slow take-up by as-synthesized SBA particles or by either as-synthesized or calcined MCM particles. Measurement of the release of platinum drugs from nanoparticles previously soaked in drug solutions showed a substantial quick release for all particles and both drugs. This was followed by a slow release of Pt species in the case of transplatin in calcined SBA.
我们报告了顺铂和反式铂抗癌药物在介孔硅纳米材料中的吸附和释放，特别强调了顺铂与其毒性小得多的异构体之间的差异。使用了两种类型的颗粒，MCM-41 和 SBA-15，要么是刚合成的，要么是经过煅烧去除模板的。通过 TEM、氮气物理吸附和元素分析对颗粒进行了表征。获得了顺铂和反式铂的紫外可见光谱，并且发现几个波段（205-210nm、210-220nm、220-235nm 和 300-330nm）的强度与药物浓度成正比，允许它们用于测量药物浓度。为了评估纳米颗粒对药物的吸附，将纳米颗粒在药物溶液中孵育，然后通过离心去除，之后用分光光度计扫描上清液以确定剩余药物。发现煅烧后的 MCM 每颗粒吸附的顺铂或反式铂比合成后的 MCM 少。SBA 纳米颗粒吸附的顺铂略多于 MCM，而吸附的反式铂略少。作为时间函数的药物吸附测量表明，所有研究的颗粒都迅速吸附药物。这种快速吸附可能与药物在颗粒的外表面上的吸附以及在合成材料的情况下通过取代表面活性剂分子或离子或通过在合成后的材料的情况下通过取代表面活性剂分子或离子有关。对于煅烧后的 SBA 颗粒，随后是药物的缓慢吸收，这可能是由于内部孔。合成后的 SBA 颗粒或合成后的或煅烧后的 MCM 颗粒都没有缓慢吸收。测量先前在药物溶液中浸泡过的纳米颗粒中铂类药物的释放，发现所有颗粒和两种药物都有大量快速释放。随后，在煅烧后的 SBA 中，反式铂的 Pt 物种释放缓慢。
